Chronic Pain & Psychiatry

Chronic pain and mental health are deeply interconnected through shared brain pathways and neurotransmitters. Depression occurs in 30-50% of chronic pain patients (3-4x higher than general population), while anxiety affects 30-40%. The relationship is bidirectional: (1) Pain increases depression risk through multiple mechanisms—activity limitation, sleep disruption, hopelessness about the future, biological changes in serotonin/norepinephrine; (2) Depression amplifies pain perception—depressed individuals have lower pain thresholds, greater pain intensity, more pain-related disability. Brain imaging shows overlapping neural circuits for pain and emotion processing (anterior cingulate cortex, insula, prefrontal cortex). Neurotransmitters like serotonin and norepinephrine regulate both mood and pain modulation, explaining why antidepressants reduce pain even in non-depressed patients. Treating the psychological aspects of chronic pain isn't about 'the pain is all in your head'—it's recognizing that pain is a complex biopsychosocial phenomenon requiring integrated treatment.

Central sensitization is a state of heightened responsiveness of the central nervous system to pain signals. Normally, pain serves as a protective warning signal. In central sensitization, the nervous system becomes 'wound up'—amplifying pain signals, maintaining pain even after tissue healing, and triggering pain from normally non-painful stimuli (allodynia). Mechanisms include: (1) Spinal cord wind-up—repeated pain signals increase responsiveness of dorsal horn neurons; (2) Reduced descending inhibition—the brain's natural pain-dampening system becomes less effective; (3) Glial cell activation—inflammatory processes in the nervous system; (4) Synaptic plasticity—long-term changes in pain pathways. Central sensitization explains conditions like fibromyalgia, chronic widespread pain, and persistent pain without identifiable tissue damage. Neuroimaging shows altered brain activity in pain processing regions. Treatment targets the nervous system rather than peripheral injury site—medications that modulate central pain processing (SNRIs, anticonvulsants, low-dose naltrexone), psychological approaches (CBT, mindfulness, acceptance), and nervous system regulation (sleep, stress management, pacing).

Many non-opioid medications effectively treat chronic pain, often with better long-term outcomes than opioids. SNRIs: Duloxetine (Cymbalta) 60-120mg and venlafaxine (Effexor XR) 150-225mg are FDA-approved for multiple pain conditions (diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain). They work by increasing serotonin and norepinephrine in pain-modulating pathways. Anticonvulsants: Gabapentin (Neurontin) 1800-3600mg and pregabalin (Lyrica) 300-600mg are highly effective for neuropathic pain by reducing excitatory neurotransmitter release. Tricyclic antidepressants: Amitriptyline, nortriptyline at low doses (10-75mg) have strong evidence for neuropathic pain and headache, though side effects limit use. Low-dose naltrexone (LDN): 1.5-4.5mg at bedtime shows promise for fibromyalgia, complex regional pain syndrome, and autoimmune-related pain by modulating glial cells and endorphins. Topicals: Lidocaine patches, capsaicin cream, compounded topicals for localized pain. NSAIDs: For inflammatory pain component, though long-term use has cardiovascular and GI risks. These medications work through different mechanisms than opioids, don't cause dependence, and target central pain processing rather than just blocking pain signals.

Pain catastrophizing is an exaggerated negative cognitive-emotional response to pain involving three components: (1) Magnification—exaggerating the threat value of pain ('This pain is unbearable'); (2) Rumination—obsessive focus on pain ('I can't stop thinking about my pain'); (3) Helplessness—perceiving inability to manage pain ('There's nothing I can do about this pain'). Measured by the Pain Catastrophizing Scale, high catastrophizing predicts worse pain outcomes—greater pain intensity, more disability, poorer treatment response, higher opioid use, and increased surgical complications. Mechanisms: Catastrophizing activates pain-related brain regions (anterior cingulate cortex, prefrontal cortex) and stress systems (cortisol, inflammatory markers), literally amplifying pain through top-down brain processes. It's not 'making up' pain—it's a cognitive style that genuinely intensifies pain perception and suffering. Risk factors include anxiety, depression, trauma history, and lack of pain self-efficacy. Treatment: CBT for chronic pain specifically targets catastrophizing through cognitive restructuring ('This pain is familiar and manageable, not catastrophic'), behavioral experiments (discovering you can do more than feared), and attention training (shifting focus from pain monitoring to valued activities). Reducing catastrophizing produces clinically meaningful reductions in pain intensity and disability.

CBT for chronic pain (CBT-CP) is an evidence-based psychological treatment targeting thoughts, emotions, and behaviors that maintain pain and disability. Unlike traditional pain treatment focusing solely on eliminating pain, CBT-CP aims to reduce suffering, improve function, and enhance quality of life even if some pain persists. Components include: (1) Pain education—understanding pain neurophysiology, the role of central sensitization, and the biopsychosocial model; (2) Cognitive restructuring—identifying and challenging pain-related thoughts (catastrophizing, fear-avoidance beliefs) and developing adaptive coping thoughts; (3) Behavioral activation and pacing—gradually increasing activity using baseline-quota approach (time-based goals rather than pain-contingent stopping), breaking boom-bust cycles; (4) Relaxation and mindfulness—reducing muscle tension, autonomic arousal, and pain-related distress; (5) Sleep hygiene and fatigue management; (6) Addressing comorbid depression and anxiety that amplify pain. Meta-analyses show CBT-CP produces small to moderate reductions in pain intensity, moderate to large reductions in disability and depression, and improvements in pain self-efficacy. Benefits persist long-term. Typically 8-12 weekly sessions, individual or group format.

Psychiatric medications used for chronic pain (SNRIs, anticonvulsants, low-dose tricyclics) are generally safe for long-term use with appropriate monitoring, especially compared to long-term opioids. SNRIs (duloxetine, venlafaxine): Long-term safety profile is well-established from depression studies. Main concerns: discontinuation syndrome if stopped abruptly (taper slowly), blood pressure monitoring, sexual side effects. No organ damage, cognitive impairment, or dependence. Anticonvulsants (gabapentin, pregabalin): Safe long-term with kidney function monitoring. Sedation often improves over time. Slight dependence potential (taper when discontinuing), but far less than opioids. Tricyclics (amitriptyline, nortriptyline): Anticholinergic side effects (dry mouth, constipation) and weight gain can be problematic. EKG monitoring in older adults. Generally safe at low doses used for pain. Low-dose naltrexone: Extremely safe with minimal side effects. Contrast with long-term opioids: tolerance (requiring escalating doses), hyperalgesia (opioids increasing pain sensitivity over time), hormonal effects, cognitive impairment, overdose risk, and severe dependence. For chronic pain, psychiatric medications offer effective pain relief without the risks associated with chronic opioid therapy. Regular follow-up ensures any side effects are managed proactively.